Page last updated: 2024-10-27

fluoxetine and Ache

fluoxetine has been researched along with Ache in 56 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

ExcerptRelevanceReference
" Fluoxetine did not significantly alter the threshold for discomfort/pain relative to placebo, either in hypersensitive (19 +/- 3 vs."9.10The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. ( Boeckxstaens, GE; Kuiken, SD; Tytgat, GN, 2003)
"Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter."9.07Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992)
"Previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-HT1A receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress."8.02Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation. ( Butkevich, IP; Mikhailenko, VA; Vershinina, EA, 2021)
"The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment."7.81Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015)
"Carisoprodol is a skeletal muscle relaxant prescribed to treat pain."7.80Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. ( Atayee, RS; Best, BM; Ma, JD; Tse, SA, 2014)
"The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain."7.75Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009)
"Amitriptyline, a non-selective noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor, has recently been demonstrated to produce a peripheral antinociceptive action in an inflammatory (formalin test) and a neuropathic pain model (spinal nerve ligation)."7.70Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. ( Esser, MJ; Reid, AR; Sawynok, J, 1999)
"Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor antidepressant."5.46Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats. ( Chang, JL; Lian, YN; Lu, Q; Wang, Y; Zhang, FM; Zhang, Y, 2017)
" Fluoxetine did not significantly alter the threshold for discomfort/pain relative to placebo, either in hypersensitive (19 +/- 3 vs."5.10The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. ( Boeckxstaens, GE; Kuiken, SD; Tytgat, GN, 2003)
"In a randomized, double-blind, parallel study, fluoxetine and amitriptyline were compared with placebo in the treatment of chronic rheumatic pain."5.08An evaluation of antidepressants in rheumatic pain conditions. ( Naidu, MU; Prasad, VB; Rani, PU; Rao, TR; Shobha, JC, 1996)
"Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter."5.07Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992)
"Previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-HT1A receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress."4.02Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation. ( Butkevich, IP; Mikhailenko, VA; Vershinina, EA, 2021)
"The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment."3.81Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015)
"Carisoprodol is a skeletal muscle relaxant prescribed to treat pain."3.80Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. ( Atayee, RS; Best, BM; Ma, JD; Tse, SA, 2014)
"The objective of this study was to investigate the effects of depression relief and pain relief on the improvement in daily functioning and quality of life (QOL) for depressed patients receiving a 6-week treatment of fluoxetine."3.79Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder. ( Chen, CC; Chen, MC; Lin, CH; Yen, YC, 2013)
" First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls."3.76Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010)
"The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain."3.75Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009)
" Synthesis and testing of a series of cyclohexanol ethylpiperazines identified ( S)-(-)- 17i (WAY-256805), a potent norepinephrine reuptake inhibitor (IC 50 = 82 nM, K i = 50 nM) that exhibited excellent selectivity over both the serotonin and dopamine transporters and was efficacious in animal models of depression, pain, and thermoregulatory dysfunction."3.74Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. ( Belardi, JK; Bray, JA; Burroughs, KD; Cohn, ST; Cosmi, SA; Deecher, DC; Gavrin, LK; Ho, DM; Johnston, GH; Koury, EJ; Leiter, J; Leventhal, L; Mahaney, PE; Mugford, CA; Platt, B; Rosenzweig-Lipson, SJ; Sabatucci, JP; Santilli, AA; Smith, VA; Stack, GP; Trybulski, EJ; Vu, TA; Ye, F; Zhang, Y, 2008)
"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain."3.73Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005)
" administration of either of two antidepressants used for the treatment of neuropathic pain, amitriptyline (10 mg/kg) and fluoxetine (5 mg/kg), to rats for 7 days modifies GABA(B) receptor function and subunit expression in the lumbar spinal cord."3.73GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. ( Duric, V; Enna, SJ; McCarson, KE; Reisman, SA; Winter, M, 2006)
" The non-selective noradrenaline (NA) and serotonin (5-HT) reuptake inhibitors imipramine, amitriptyline and clomipramine displayed anti-inflammatory activity in the carrageenan model of paw inflammation."3.72Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. ( Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003)
"Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals."3.72Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004)
"The acute effects of various doses of two selective serotonin reuptake inhibitors (fluoxetine and fluvoxamine) on thermal and electrical stimulation-induced pain were investigated in drug-naive Wistar rats."3.70Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation. ( Dirksen, R; Van Luijtelaar, EL; Van Rijn, CM, 1998)
"Amitriptyline, a non-selective noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor, has recently been demonstrated to produce a peripheral antinociceptive action in an inflammatory (formalin test) and a neuropathic pain model (spinal nerve ligation)."3.70Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. ( Esser, MJ; Reid, AR; Sawynok, J, 1999)
"Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i."3.69The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997)
"The goal of treating major depressive disorder is to achieve remission."2.76Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. ( Chen, CC; Juo, SH; Lane, HY; Lin, CH; Yen, CF, 2011)
"Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning."2.42The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. ( Fava, M, 2003)
"The adjusted incidence rate of opioid overdose in those using inhibiting SSRIs at the time of oxycodone initiation (9."1.72Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. ( Bykov, K; Gagne, JJ; Yoshida, K; Yunusa, I, 2022)
"Animals with PTSD-like symptoms showed an increase in the number of flinches in the formalin test and a reduction in mechanical threshold in the von Frey test at both retention intervals."1.62Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation. ( de Souza, GR; Giusti-Paiva, A; Kalil-Cutti, B; Vieira, JS; Vilela, FC, 2021)
"This study contributes to possible treatments for pain in individuals exposed to early life stress."1.62Maternal separation increases pain sensitivity by reducing the activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in locus coeruleus. ( da Silva, JRT; da Silva, ML; Giusti-Paiva, A; Kalil-Cutti, B; Vieira, JS; Vilela, FC; Vitor-Vieira, F, 2021)
"Pain is a significant public health problem, and assessment of pain-related impairment of behavior is a key clinical indicator and treatment target."1.51Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice. ( Alexander, KS; Miller, LL; Patton, TB; Rodriguez, TR; Sarfo, AN, 2019)
"Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor antidepressant."1.46Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats. ( Chang, JL; Lian, YN; Lu, Q; Wang, Y; Zhang, FM; Zhang, Y, 2017)
"Mechanical hyperalgesia was assessed after acute treatment with TAT-2ASCV or/and fluoxetine (SSRI) 2."1.39Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats. ( Aissouni, Y; Chalus, M; Courteix, C; Dupuis, A; Eschalier, A; Hernández, A; Marin, P; Pelissier, T; Pichon, X; Privat, AM; Wattiez, AS, 2013)
"Pretreatment with seganserin, a 5-HT(2) receptor antagonist (2 mg/kg, i."1.31Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice. ( Kaur, G; Kulkarni, SK, 2002)
"When fluoxetine (250 microM) was present in the perfusing solution, the levels of beta-endorphin in the dialysates from the arcuate nucleus and nucleus accumbens increased two- to threefold."1.30Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study. ( Nakash, R; Yadid, G; Zangen, A, 1999)
"Fluoxetine treatment resulted in a nonsignificant increase in nociceptive response at 30 min posttreatment which returned to the baseline by 1 h."1.29Serotonin modulation of pain responsiveness in the aged rat. ( Akunne, HC; Soliman, KF, 1994)

Research

Studies (56)

TimeframeStudies, this research(%)All Research%
pre-19902 (3.57)18.7374
1990's15 (26.79)18.2507
2000's15 (26.79)29.6817
2010's17 (30.36)24.3611
2020's7 (12.50)2.80

Authors

AuthorsStudies
Mahaney, PE2
Gavrin, LK1
Trybulski, EJ2
Stack, GP1
Vu, TA1
Cohn, ST2
Ye, F1
Belardi, JK1
Santilli, AA1
Sabatucci, JP1
Leiter, J1
Johnston, GH2
Bray, JA2
Burroughs, KD1
Cosmi, SA2
Leventhal, L2
Koury, EJ2
Zhang, Y2
Mugford, CA1
Ho, DM1
Rosenzweig-Lipson, SJ1
Platt, B1
Smith, VA2
Deecher, DC2
Rephaeli, A1
Gil-Ad, I1
Aharoni, A1
Tarasenko, I1
Tarasenko, N1
Geffen, Y1
Halbfinger, E1
Nisemblat, Y1
Weizman, A1
Nudelman, A1
Vu, AT1
Zhang, P1
Kim, CY1
Harrison, JE1
Whiteside, GT1
Kennedy, JD1
Vivier, D1
Bennis, K1
Lesage, F1
Ducki, S1
Huang, Z1
Yin, L1
Guan, L1
Li, Z1
Tan, C1
Yunusa, I1
Gagne, JJ1
Yoshida, K1
Bykov, K1
Qi, M1
Li, C1
Li, J1
Zhu, XN1
Lu, C1
Luo, H1
Feng, Y1
Cai, F1
Sun, X1
Li, ST1
Hu, J1
Luo, Y1
Butkevich, IP3
Mikhailenko, VA3
Vershinina, EA1
Vilela, FC2
Vieira, JS2
Vitor-Vieira, F1
Kalil-Cutti, B2
da Silva, JRT1
Giusti-Paiva, A2
da Silva, ML1
de Souza, GR1
Lian, YN1
Chang, JL1
Lu, Q1
Wang, Y1
Zhang, FM1
Hernandez-Leon, A1
Fernández-Guasti, A1
Martínez, A1
Pellicer, F1
González-Trujano, ME1
Alexander, KS1
Rodriguez, TR1
Sarfo, AN1
Patton, TB1
Miller, LL1
Lin, CH3
Yen, YC1
Chen, MC1
Chen, CC2
Cervantes-Durán, C1
Rocha-González, HI1
Granados-Soto, V1
Wattiez, AS1
Pichon, X1
Dupuis, A1
Hernández, A1
Privat, AM1
Aissouni, Y1
Chalus, M1
Pelissier, T1
Eschalier, A1
Marin, P1
Courteix, C1
Tse, SA1
Atayee, RS1
Ma, JD1
Best, BM1
Hong, J1
Novick, D1
Montgomery, W1
Moneta, MV1
Dueñas, H1
Peng, X1
Haro, JM1
Lin, HS1
Wang, FC1
Cravero, C1
Guinchat, V1
Barete, S1
Consoli, A1
Boyce-Rustay, JM1
Zhong, C1
Kohnken, R1
Baker, SJ1
Simler, GH1
Wensink, EJ1
Decker, MW1
Honore, P1
Song, Z1
Meyerson, BA1
Linderoth, B1
Lane, HY1
Juo, SH1
Yen, CF1
Rico-Villademoros, F1
Yen, HL1
Chan, W1
Abdel-Salam, OM2
Nofal, SM1
El-Shenawy, SM1
Fava, M1
Kuiken, SD1
Tytgat, GN1
Boeckxstaens, GE1
Iyengar, S1
Webster, AA1
Hemrick-Luecke, SK1
Xu, JY1
Simmons, RM1
Liappas, IA1
Dimopoulos, NP1
Mellos, E1
Gitsa, OE1
Liappas, AI1
Rabavilas, AD1
Pedersen, LH1
Nielsen, AN1
Blackburn-Munro, G1
McCarson, KE1
Duric, V1
Reisman, SA1
Winter, M1
Enna, SJ1
Gameiro, GH1
Gameiro, PH1
Andrade, Ada S1
Pereira, LF1
Arthuri, MT1
Marcondes, FK1
Veiga, MC1
Anjaneyulu, M1
Chopra, K1
Akunne, HC1
Soliman, KF1
Lauterbach, EC1
Balon, R1
Yeragani, VK1
Pohl, R1
Ramesh, C1
Rani, PU1
Naidu, MU1
Prasad, VB1
Rao, TR1
Shobha, JC1
Symonds, A1
Liu, CY1
Yang, YY1
Wang, SJ1
Fuh, JL1
Liu, HC1
Jett, MF1
McGuirk, J1
Waligora, D1
Hunter, JC1
Page, ME1
Abercrombie, ED1
Dirksen, R1
Van Luijtelaar, EL1
Van Rijn, CM1
Gambarana, C1
Ghiglieri, O1
Tolu, P1
De Montis, MG1
Giachetti, D1
Bombardelli, E1
Tagliamonte, A1
Sawynok, J1
Esser, MJ1
Reid, AR1
Zangen, A1
Nakash, R1
Yadid, G1
McCleane, G1
Kaur, G1
Kulkarni, SK1
Petitto, JM1
Mundle, LB1
Nagy, BR1
Evans, DL1
Golden, RN1
Max, MB1
Lynch, SA1
Muir, J1
Shoaf, SE1
Smoller, B1
Dubner, R1
Stalheim, RM1
Hynes, MD1
Lochner, MA1
Bemis, KG1
Hymson, DL1
Izenwasser, S1
Kornetsky, C1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Influence of Oxycodone on Individuals Taking an SSRI[NCT05730062]Phase 155 participants (Anticipated)Interventional2023-03-15Not yet recruiting
Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848]Phase 422 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Numeric Pain Rating Scale (NPRS)

Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

,
Interventionunits on a scale (Mean)
Average Baseline NPRS ScoreAverage NPRS after 1000 Hz. stimulationAverage NPRS after standard stimulationAverage NPRS after Wash offBest Baseline NPRS scoreBest NPRS score after 1000 Hz. stimulationBest NPRS score after standard stimulationBest NPRS after Wash offWorst Baseline NPRS scoreWorst NPRS score after 1000 Hz. stimulationWorst NPRS score after standard stimulationWorst NPRS after Wash off
Treatment Group A6.093.735.646.453.722.643.464.547.906.648.188.72
Treatment Group B6.273.826.097.184.452.184.455.368.096.648.368.81

Oswestry Disability Index Questionnaire (ODI).

ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

,
Interventionunits on a scale (Mean)
Baseline ODI scoreODI after 1000 Hz. stimluationODI after standard stimulationODI after wash off
Treatment Group A47.4939.2349.6352.87
Treatment Group B51.2533.7749.0556.77

Patient's Global Impression of Change (PGIC)

PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

,
Interventionunits on a scale (Mean)
PGIC After 1000 Hz. stimulationPGIC after standard stimulationPGIC after Wash off
Treatment Group A4.272.541.45
Treatment Group B5.912.451.27

Preferability

At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4

,
Interventionparticipants (Number)
Subjects who prefer 1000 Hz. stimulationSubjects who prefer standard stimulation
Treatment Group A83
Treatment Group B101

Reviews

2 reviews available for fluoxetine and Ache

ArticleYear
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
    Journal of medicinal chemistry, 2016, 06-09, Volume: 59, Issue:11

    Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc

2016
The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 13

    Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Norepi

2003

Trials

4 trials available for fluoxetine and Ache

ArticleYear
Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal

2011
The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2003, Volume: 1, Issue:3

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine

2003
An evaluation of antidepressants in rheumatic pain conditions.
    Anesthesia and analgesia, 1996, Volume: 83, Issue:2

    Topics: Adult; Amitriptyline; Analgesics; Antidepressive Agents, Second-Generation; Antidepressive Agents, T

1996
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
    The New England journal of medicine, 1992, May-07, Volume: 326, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa

1992

Other Studies

50 other studies available for fluoxetine and Ache

ArticleYear
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13

    Topics: Animals; Cell Line; Cyclohexanols; Ethylamines; Female; Humans; Male; Mice; Models, Molecular; Molec

2008
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
    Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

    Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam

2009
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmi

2010
Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects.
    Bioorganic & medicinal chemistry letters, 2020, 12-15, Volume: 30, Issue:24

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Depression; Drug Discovery; In

2020
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
    JAMA network open, 2022, 02-01, Volume: 5, Issue:2

    Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Comorbidity; Depression; Emergency Medical Services

2022
Fluoxetine reverses hyperactivity of anterior cingulate cortex and attenuates chronic stress-induced hyperalgesia.
    Neuropharmacology, 2022, 12-01, Volume: 220

    Topics: Animals; Fluoxetine; Gyrus Cinguli; Hyperalgesia; Mice; Pain; Serotonin

2022
Effects of Stress Exposure during Adolescent Period on Inflammatory Pain Response, Psychoemotional Behavior, and Action of Antidepressants in Prenatally Stressed Adult Male Rats.
    Bulletin of experimental biology and medicine, 2020, Volume: 169, Issue:3

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Buspirone; Female; Fluoxetine; Inflammation; Male;

2020
Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation.
    Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:6

    Topics: Animals; Buspirone; Female; Fluoxetine; Male; Pain; Pregnancy; Rats

2021
Maternal separation increases pain sensitivity by reducing the activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in locus coeruleus.
    Neuroscience letters, 2021, 03-23, Volume: 748

    Topics: Adrenergic Neurons; Animals; Dorsal Raphe Nucleus; Fluoxetine; Locus Coeruleus; Maternal Deprivation

2021
Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation.
    Behavioural brain research, 2021, 08-06, Volume: 411

    Topics: Adrenergic Neurons; Animals; Behavior, Animal; Fluoxetine; Male; Norepinephrine; Pain; Pain Manageme

2021
Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats.
    Neuroscience letters, 2017, 06-09, Volume: 651

    Topics: Animals; Antidepressive Agents, Second-Generation; Disease Models, Animal; Fluoxetine; Hyperalgesia;

2017
Sleep architecture is altered in the reserpine-induced fibromyalgia model in ovariectomized rats.
    Behavioural brain research, 2019, 05-17, Volume: 364

    Topics: Animals; Disease Models, Animal; Female; Fibromyalgia; Fluoxetine; Hyperalgesia; Ovariectomy; Pain;

2019
Prenatal Stimulation of 5-HT
    Bulletin of experimental biology and medicine, 2019, Volume: 166, Issue:3

    Topics: Adaptation, Psychological; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Buspirone; Depressi

2019
Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice.
    Behavioural pharmacology, 2019, Volume: 30, Issue:6

    Topics: Analgesics, Opioid; Animals; Behavior, Animal; Bupropion; Citalopram; Conditioning, Operant; Dopamin

2019
Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Dec-02, Volume: 47

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2013
Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats.
    Neuroscience, 2013, Nov-12, Volume: 252

    Topics: Animals; Female; Fluoxetine; Pain; Peripheral Nervous System; Rats; Rats, Wistar; Receptors, Seroton

2013
Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Animals; Bicuculline; Carrageenan; Disks Large Homolog 4 Protein; Fluorobenzenes; Fluoxetine; Hypera

2013
Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.
    Journal of analytical toxicology, 2014, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Carisoprodol; Chromatogra

2014
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:1

    Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluo

2016
Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Female; Fl

2015
Cornelia de Lange and Ehlers-Danlos: comorbidity of two rare syndromes.
    BMJ case reports, 2016, Feb-01, Volume: 2016

    Topics: Adult; Anemia, Iron-Deficiency; Antidepressive Agents, Second-Generation; Cognitive Behavioral Thera

2016
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
    Neuropharmacology, 2010, Volume: 58, Issue:2

    Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo

2010
The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy.
    Anesthesia and analgesia, 2011, Volume: 113, Issue:5

    Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; C

2011
On the interpretation of odds ratios.
    The Clinical journal of pain, 2012, Volume: 28, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; In

2012
An East-West approach to the management of central post-stroke pain.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:1

    Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon

2003
Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
    Pharmacological research, 2003, Volume: 48, Issue:2

    Topics: Amitriptyline; Analysis of Variance; Animals; Antidepressive Agents; Carrageenan; Clomipramine; Dise

2003
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:2

    Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl

2004
Oral transmucosal abuse of transdermal fentanyl.
    Journal of psychopharmacology (Oxford, England), 2004, Volume: 18, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug A

2004
Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats.
    TheScientificWorldJournal, 2005, Aug-08, Volume: 5

    Topics: Acetic Acid; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin;

2005
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
    Psychopharmacology, 2005, Volume: 182, Issue:4

    Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio

2005
GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants.
    Brain research, 2006, Jan-12, Volume: 1068, Issue:1

    Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation;

2006
Nociception- and anxiety-like behavior in rats submitted to different periods of restraint stress.
    Physiology & behavior, 2006, Apr-15, Volume: 87, Issue:4

    Topics: Acute Disease; Adrenocorticotropic Hormone; Analgesics, Opioid; Animals; Anxiety; Chronic Disease; C

2006
Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice.
    European journal of pharmacology, 2006, May-24, Volume: 538, Issue:1-3

    Topics: Analgesics; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fl

2006
Serotonin modulation of pain responsiveness in the aged rat.
    Pharmacology, biochemistry, and behavior, 1994, Volume: 48, Issue:2

    Topics: Aging; Animals; Drug Synergism; Fluoxetine; Male; Methysergide; Morphine; Pain; Pain Measurement; Ra

1994
Fluoxetine withdrawal and thalamic pain.
    Neurology, 1994, Volume: 44, Issue:5

    Topics: Cerebral Infarction; Depression; Female; Fluoxetine; Humans; Middle Aged; Pain; Thalamus; Time Facto

1994
Sexual dysfunction during antidepressant treatment.
    The Journal of clinical psychiatry, 1993, Volume: 54, Issue:6

    Topics: Adult; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depressive Disorder;

1993
The mind and the butt.
    Psychiatric services (Washington, D.C.), 1996, Volume: 47, Issue:2

    Topics: Adult; Buttocks; Combined Modality Therapy; Depression, Postpartum; Female; Fluoxetine; Humans; Obse

1996
Fluoxetine-related suicidality and muscle aches in a patient with poststroke depression.
    Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:6

    Topics: Aged; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Depressive Disorder; Fluo

1996
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
    Pain, 1997, Volume: 69, Issue:1-2

    Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr

1997
An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1997, Volume: 16, Issue:6

    Topics: Animals; Extracellular Space; Fluoxetine; Handling, Psychological; Hippocampus; Locus Coeruleus; Mal

1997
Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation.
    Pharmacology, biochemistry, and behavior, 1998, Volume: 60, Issue:3

    Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Fluvoxa

1998
Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1999, Volume: 21, Issue:2

    Topics: Acute Disease; Animals; Appetite; Benzazepines; Chronic Disease; Disease Models, Animal; Electroshoc

1999
Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.
    Pain, 1999, Volume: 82, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Caffeine; Desipramine; Drug Evaluation, Precli

1999
Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study.
    Journal of neurochemistry, 1999, Volume: 73, Issue:6

    Topics: 5,7-Dihydroxytryptamine; Affect; Animals; Antidepressive Agents; Arcuate Nucleus of Hypothalamus; be

1999
Peripheral antinociceptive actions of desimipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.
    Pain, 2000, Volume: 85, Issue:1-2

    Topics: Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents,

2000
Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice.
    Brain research, 2002, Jul-12, Volume: 943, Issue:2

    Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Brain; Depression; Disease Models, An

2002
Improvement of arthritis with fluoxetine.
    Psychosomatics, 1992,Summer, Volume: 33, Issue:3

    Topics: Arthritis; Female; Fluoxetine; Humans; Middle Aged; Migraine Disorders; Pain; Selective Serotonin Re

1992
A question about Prozac and arthralgias.
    North Carolina medical journal, 1990, Volume: 51, Issue:4

    Topics: Female; Fluoxetine; Humans; Joint Diseases; Middle Aged; Pain

1990
Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors.
    Life sciences, 1985, Jun-17, Volume: 36, Issue:24

    Topics: Animals; Binding, Competitive; Brain; Discrimination, Psychological; Drug Synergism; Enkephalin, Leu

1985
Potentiation of morphine analgesia by D-amphetamine is mediated by norepinephrine and not dopamine.
    Pain, 1988, Volume: 33, Issue:3

    Topics: Amphetamine; Analgesics; Animals; Dopamine; Dopamine Antagonists; Drug Synergism; Electric Stimulati

1988